Supplementary Materials

Supplementary Material for:

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Prasad S. Adusumilli,* Leonid Cherkassky, Jonathan Villena-Vargas, Christos Colovos, Elliot Servais, Jason Plotkin, David R. Jones, Michel Sadelain*

*Corresponding author. E-mail: adusumip{at}mskcc.org (P.S.A.); sadelaim{at}mskcc.org (M.S.)

Published 5 November 2014, Sci. Transl. Med. 6, 261ra151 (2014)
DOI: 10.1126/scitranslmed.3010162

This PDF file includes:

  • Fig. S1. Mesothelin-targeted CAR T cells demonstrate antigen-specific effector function.
  • Fig. S2. Intrapleural administration of mesothelin-targeted CAR T cells achieves durable tumor regression and a rapid accumulation of intratumoral T cells.
  • Fig. S3. Mesothelin-targeted CAR T cells lyse target cells via granzyme-perforin and CD4+ T cells are induced to up-regulate granzyme B.
  • Fig. S4. CAR T cell cytolytic function is proportional to level of target antigen expression.
  • Fig. S5. Gating strategy for flow cytometry.
  • Table S1. CAR T cell doses in preclinical and clinical studies.
  • Table S2. Raw data and statistical significance testing for Fig. 1.
  • Table S3. Raw data and statistical significance for Fig. 2.
  • Table S4. Raw data for Fig. 3.
  • Table S5. Raw data and statistical significance testing for Fig. 4.
  • Table S6. Raw data and statistical significance testing for Fig. 5.
  • Table S7. Raw data and statistical significance testing for Fig. 6.
  • Table S8. Raw data and statistical significance testing for Fig. 7.
  • Table S9. Raw data and statistical significance testing for Fig. 8.

[Download PDF]